Acumen Pharmaceuticals, Inc. (ABOS) |
|
3.92 -0.06 (-1.51%)
|
03-24 11:58 |
|
Open: |
4.05 |
Pre. Close: |
3.98 |
|
High:
|
4.02 |
Low:
|
3.8298 |
|
Volume:
|
19,878 |
Market Cap:
|
160(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 10:41:25 AM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 5.97 One year: 6.97 |
| Support: |
Support1: 3.74 Support2: 3.11 |
| Resistance: |
Resistance1: 5.11 Resistance2: 5.96 |
| Pivot: |
4.43  |
| Moving Average: |
MA(5): 3.92  MA(20): 4.62
MA(100): 5.59 MA(250): 5.37 |
| MACD: |
MACD(12,26): -0.5 Signal(9): -0.4 |
| Stochastic oscillator: |
%K(14,3): 12.7 %D(3): 10.9 |
| RSI: |
RSI(14): 30.6 |
| 52-week: |
High: 10.97 Low: 3.01 |
| Average Vol(K): |
3-Month: 80 (K) 10-Days: 121 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ABOS ] has closed above bottom band by 29.8%. Bollinger Bands are 91.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.26 - 4.29 |
4.29 - 4.31 |
|
Low:
|
3.79 - 3.81 |
3.81 - 3.83 |
|
Close:
|
3.94 - 3.98 |
3.98 - 4.02 |
|
Company Description |
|
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia. |
Headline News |
Thu, 16 Mar 2023
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Update - MarketBeat
Sat, 11 Mar 2023
Moore Capital Management LP buys 64,420 Acumen ... - Best Stocks
Fri, 10 Mar 2023
Moore Capital Management LP Acquires 64420 Shares of Acumen ... - MarketBeat
Wed, 08 Mar 2023
Acumen Pharmaceuticals to Participate in the Needham ... - InvestorsObserver
Mon, 13 Feb 2023
Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of ... - GlobeNewswire
Wed, 04 Jan 2023
Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
41 (M) |
| Shares Float |
14 (M) |
|
% Held by Insiders
|
15.5 (%) |
|
% Held by Institutions
|
74.3 (%) |
|
Shares Short
|
634 (K) |
|
Shares Short P.Month
|
610 (K) |
Stock Financials |
|
EPS
|
1.11 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
4.86 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-11.3 |
|
Return on Equity (ttm)
|
-17.9 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-0.31 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.97 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-28 (M) |
|
Levered Free Cash Flow
|
-15 (M) |
Stock Valuations |
|
PE Ratio
|
3.53 |
|
PEG Ratio
|
-0.5 |
|
Price to Book value
|
0.8 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-5.83 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
